7Baggers

OptimizeRx Quarterly Income Statements Chart

Quarterly
 | 
Annual
 
 Revenue  
 Gross Profit  
 Operating Profit  
 Net Income  
20181231 20190331 20190630 20190930 20191231 20200331 20200630 20200930 20201231 20210331 20210630 20210930 20211231 20220331 20220630 20220930 20221231 20230331 20230630 20230930 -7.0688.1183.26278.42373.59468.75563.91659.07Milllion

OptimizeRx Quarterly Income Statements Table

Quarterly
 | 
Annual
 
Unit: USD2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31 2009-12-31 2009-09-30 2009-06-30 2009-03-31 2008-12-31 2008-09-30 2008-06-30 2008-03-31 
  revenue16,331,484 13,818,166 13,002,910 19,654,457 15,085,504 13,978,665 13,731,530 20,312,797 16,124,951 13,625,639 11,229,211 16,426,301 10,519,191 8,783,230 7,584,602 7,379,782 5,002,767 7,006,291 5,209,434 6,579,268 5,415,384 5,099,474 4,112,237 4,006,919 3,102,607 2,865,823 2,152,073 2,292,518 1,786,137 1,913,299 1,759,528 2,020,259 2,007,409 1,705,457 1,487,553 2,111,187 1,620,215 1,454,214 1,317,347 1,810,610 1,373,029 1,104,087 669,290 750,719 453,154 515,423 329,403 325,910 191,593 200,174 393,843 12,386 40,676 16,720 1,283 15,095 6,908 3,449 1,271 15,369 1,111 16,679 50,527 
  cost of revenue6,531,183 5,993,145 5,569,621 7,200,029 5,664,733 4,988,716 5,629,858 7,920,984 7,047,832 5,580,964 5,104,603 7,822,280 4,504,844 3,639,016 3,241,763 2,906,933 1,981,143 2,687,143 1,583,480 2,485,855 2,268,968 2,236,751 2,008,092 1,483,671 1,703,676 1,605,534 1,381,733 872,375 723,396 922,832 892,793 939,020 1,044,415 882,327 756,440 1,323,777 858,898 540,048 498,810 1,153,191 376,831 197,200 40,203 76,205 291,042 292,980 75,438 2,647,059 352,013 
  gross profit9,800,301 7,825,021 7,433,289 12,454,428 9,420,771 8,989,949 8,101,672 12,391,813 9,077,119 8,044,675 6,124,608 8,604,021 6,014,347 5,144,214 4,342,839 4,472,849 3,021,624 4,319,148 3,625,954 4,093,413 3,146,416 2,862,723 2,104,145 2,523,248 1,398,931 1,260,289 770,340 1,420,143 1,062,741 990,467 866,735 1,081,239 962,994 823,130 731,113 787,410 761,317 914,166 818,537 657,419 996,198 906,887 629,087 750,719 453,154 439,218 329,403 325,910 -99,449 -92,806 318,405 12,386 40,676 16,720 1,283 -2,631,964 6,908 -348,564 1,271 15,369 1,111 16,679 50,527 
  operating expenses                                                               
  research and development-626,533 578,054 607,003 558,658 1,240,016 1,034,281 221,891 218,096 235,744 114,604 119,372 222,374 635,244 103,172 88,267 182,339 153,773 97,211 72,796 74,616 107,751 75,761 56,445 50,414 63,268 78,437 
  sales, general and administrative                                                               
  total operating expenses13,353,789 12,706,889 14,496,475 13,318,776 13,177,530 12,898,479 11,862,773 11,770,733 9,038,929 7,704,536 6,762,916 7,247,553 6,191,069 6,200,027 6,602,091 6,791,311 4,685,528 3,839,105 3,493,789 4,218,860 2,923,238 2,589,126 2,304,343 2,762,553 2,028,589 1,630,853 1,660,778 1,898,073 1,311,959 1,432,982 1,228,564 1,497,187 875,425 980,659 842,609 712,795 1,155,933 967,070 1,071,958 701,751 985,504 552,766 733,969 631,787 559,305 591,628 630,322 1,120,427 482,635 493,154 469,281 216,229 545,889 892,083 263,094 407,951 534,065 355,462 1,376,304 953,453 162,519 218,927 266,109 
  operating income-3,553,487 -4,881,868 -7,063,186 -864,348 -3,756,759 -3,908,530 -3,761,101 621,080 38,190 340,139 -638,308 1,356,468 -176,722 -1,055,813 -2,259,252 -2,318,462 -1,987,310 480,043 132,165 -125,447 223,178 273,597 -191,196 -239,305 -629,658 -370,564 -890,438 -367,930 -249,218 -602,515 -361,829 -415,949 87,569 -157,529 -111,497 74,615 -394,616 -52,904 -653,421 -44,332 10,694 354,121 -104,882 118,932 -106,151 -76,205 -300,919 -794,517 -291,042 -292,980 -75,438 -203,843 -505,213 -875,363 -261,811 -392,856 -527,157 -352,013 -1,375,033 -938,084 -161,408 -202,248 -215,582 
  net income-2,865,297 -4,161,449 659,074,286 212,676 -3,176,825 -3,860,898 -3,761,095 623,462 39,894 352,100 -637,377 1,357,166 -282,894 -1,077,468 -2,203,931 -1,984,780 -1,570,942 406,617 6,529 -109,914 244,928 280,509 -189,179 -237,059 -622,786 -361,501 -882,682 -352,750 -242,584 -591,933 -351,916 -414,650 87,937 -157,225 -111,201 74,917 -394,314 -52,681 -653,315 -44,262 10,776 354,159 -104,826 118,993 -106,174 -76,059 -300,734 -503,768 -969,379 -432,683 -214,932 -368,575 -504,578 -874,903 -260,967 -2,330,614 -522,207 -342,145 -1,360,723 -3,345,895 -161,408 -535,238 -548,486 

We provide you with 20 years income statements for OptimizeRx stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of OptimizeRx stock. Explore the full financial landscape of OptimizeRx stock with our expertly curated income statements.

The information provided in this report about OptimizeRx stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.